<--- Back to Details
First PageDocument Content
Pharmacology / Pharmaceutical sciences / Specialty drugs / Chemistry / Breakthrough therapy / Gilead Sciences / Organofluorides / Propionates / Sofosbuvir / Ledipasvir / Hepatitis C / Prescription costs
Date: 2014-09-26 10:10:18
Pharmacology
Pharmaceutical sciences
Specialty drugs
Chemistry
Breakthrough therapy
Gilead Sciences
Organofluorides
Propionates
Sofosbuvir
Ledipasvir
Hepatitis C
Prescription costs

Add to Reading List

Source URL: www.hepcoalition.org

Download Document from Source Website

File Size: 285,38 KB

Share Document on Facebook

Similar Documents

1978 Non-adherence is the most important risk factor for ledipasvir/sofosbuvir HCV treatment failure in the real world. Dost Sarpel1, Isaac Wasserman2, Alyssa L. Trochtenberg2, Kian Bichoupan1, David P. Del Bello1, Ponni

1978 Non-adherence is the most important risk factor for ledipasvir/sofosbuvir HCV treatment failure in the real world. Dost Sarpel1, Isaac Wasserman2, Alyssa L. Trochtenberg2, Kian Bichoupan1, David P. Del Bello1, Ponni

DocID: 1t14c - View Document

Microsoft Word - GILEAD BRIEFING

Microsoft Word - GILEAD BRIEFING

DocID: 1r2Vm - View Document

--------------------------------CONTRAINDICATIONS-----------------------------­ EPCLUSA and ribavirin combination regimen is contraindicated in patients for whom ribavirin is contraindicated (4) HIGHLIGHTS OF PRESCRIBIN

--------------------------------CONTRAINDICATIONS-----------------------------­ EPCLUSA and ribavirin combination regimen is contraindicated in patients for whom ribavirin is contraindicated (4) HIGHLIGHTS OF PRESCRIBIN

DocID: 1qjt9 - View Document

Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English transl

Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English transl

DocID: 1qgyA - View Document

Guidelines  EASL Recommendations on Treatment of Hepatitis C 2015 European Association for the Study of the Liver ⇑  Introduction

Guidelines EASL Recommendations on Treatment of Hepatitis C 2015 European Association for the Study of the Liver ⇑ Introduction

DocID: 1pRH9 - View Document